Showing papers for search query "Cyber-physical+system"+OR+"Industrial+control+system"+OR+"ICS"+OR+"SCADA"+OR+"Distributed+control+system"+OR+"DCS"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"

     Search term "Cyber-physical+system"+OR+"Industrial+control+system"+OR+"ICS"+OR+"SCADA"+OR+"Distributed+control+system"+OR+"DCS"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"
     Title Banning a risky product cannot improve any consumer's welfare (properly understood), with applications to FDA testing requirements
     Author ['R Higgs']
     Venue The Review of Austrian Economics
     Year 1994
     Abstract Page 1. Banning a Risky Product Cannot Improve Any Consumer's Welfare (Properly Understood), with Applications to FDA Testing Requirements Robert Higgs N~oclassical  consumers. Applications to FDA Testing Requirements Since
     Url https://link.springer.com/content/pdf/10.1007/BF01101940.pdf


     Search term "Cyber-physical+system"+OR+"Industrial+control+system"+OR+"ICS"+OR+"SCADA"+OR+"Distributed+control+system"+OR+"DCS"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"
     Title Establishing compliance of batch SCADA systems with FDA CGMP 21 CFR Part 11
     Author ['SL Whitman']
     Venue Pharmaceutical Technology
     Year 2001
     Abstract but compliance can be established with formal re- qualification testing that challenges  This policy implies FDA expectations of a comprehensive assessment, identification of deviations  defined system “types” (ie – desktop, lab analytical, LIMS, QA support, DCS, SCADA, MES, etc
     Url https://www.controlglobal.com/assets/Media/News/080828_WBF_Estab.%20Compliance.pdf


     Search term "Cyber-physical+system"+OR+"Industrial+control+system"+OR+"ICS"+OR+"SCADA"+OR+"Distributed+control+system"+OR+"DCS"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"
     Title Recommendations from the iSBTc-SITC/FDA/NCI workshop on immunotherapy biomarkers
     Author ['LH Butterfield', 'AK Palucka', 'CM Britten']
     Venue Clinical Cancer …
     Year 2011
     Abstract Skip to main content. AACR Publications: Blood Cancer Discovery; Cancer Discovery; Cancer Epidemiology, Biomarkers & Prevention; Cancer Immunology Research; Cancer Prevention Research; Cancer Research; Clinical Cancer
     Url https://clincancerres.aacrjournals.org/content/17/10/3064.short


     Search term "Cyber-physical+system"+OR+"Industrial+control+system"+OR+"ICS"+OR+"SCADA"+OR+"Distributed+control+system"+OR+"DCS"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"
     Title Pharmacogenomics testing: What the FDA says
     Author ['VL Ellingrod']
     Venue Current Psychiatry
     Year 2019
     Abstract Until recently, the FDA was fairly quiet regarding pharmacogenom- ics tests because most of these tests  sified these platforms as medical devices; however, they are reviewed by the FDA only if  for moderate- to high- risk medical purposes, or if the results of the testing may have
     Url https://mdedge-files-live.s3.us-east-2.amazonaws.com/files/s3fs-public/CP01804029.PDF


     Search term "Cyber-physical+system"+OR+"Industrial+control+system"+OR+"ICS"+OR+"SCADA"+OR+"Distributed+control+system"+OR+"DCS"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"
     Title Practical testing of solid-state stability of pharmaceuticals
     Author ['L Chafetz']
     Venue Journal of pharmaceutical sciences
     Year 1992
     Abstract A final caution to users of accelerated stability testing is on the use of unrealistic temperatures  Sci. 1980,69, 1099. Mataui, F.; Robertson, DL; LaFontaine, P.; Kolasinski, H.; Lovering, EG J . Pharm. Sci. 1978,67,646. Human Drugs and Bwlo ics, FDA, Department of Health an f
     Url https://www.jpharmsci.org/article/S0022-3549(15)48721-0/pdf


     Search term "Cyber-physical+system"+OR+"Industrial+control+system"+OR+"ICS"+OR+"SCADA"+OR+"Distributed+control+system"+OR+"DCS"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"
     Title Review and analysis of FDA approved drugs using lipid-based formulations
     Author ['R Savla', 'J Browne', 'V Plassat', 'KM Wasan']
     Venue Drug development and …
     Year 2017
     Abstract Restricting our analysis to this set of data provides some degree of assurance that these formulations are robust and have withstood the rigors of in vitro, animal, and human testing  Published online: 06 July 2017. Figure 4. DCS plot of FDA approved drugs formulated using
     Url https://www.tandfonline.com/doi/abs/10.1080/03639045.2017.1342654


     Search term "Cyber-physical+system"+OR+"Industrial+control+system"+OR+"ICS"+OR+"SCADA"+OR+"Distributed+control+system"+OR+"DCS"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"
     Title The role of the FDA in the effort against AIDS.
     Author ['FE Young']
     Venue Public health reports
     Year 1988
     Abstract the Division of Cytokine Biology within the Center for Biolog- ics Evaluation and  In this regard, FDA virologists have been heavily involved in research and  focused on developing methodologies for standardization, preclinical characterization, clini- cal testing, and evaluation of
     Url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1478072/


     Search term "Cyber-physical+system"+OR+"Industrial+control+system"+OR+"ICS"+OR+"SCADA"+OR+"Distributed+control+system"+OR+"DCS"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"
     Title Federal neglect: regulation of genetic testing
     Author ['GH Javitt', 'K Hudson']
     Venue Issues in Science and Technology
     Year 2006
     Abstract although the government announced in 2000 that it would establish a genet- ics specialty area  between a patient's personal physician and a physician- employee of the testing laboratory. Nor does the FDA reg- ulate the claims that laboratories make about tests developed using
     Url https://www.jstor.org/stable/43314223


     Search term "Cyber-physical+system"+OR+"Industrial+control+system"+OR+"ICS"+OR+"SCADA"+OR+"Distributed+control+system"+OR+"DCS"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"
     Title FDA oversight of cell therapy clinical trials
     Author ['P Au', 'DA Hursh', 'A Lim', 'MC Moos', 'SS Oh']
     Venue Science translational …
     Year 2012
     Abstract input to FDA (1). By following such an approach, FDA's Center for Biolog- ics Evaluation and  ly accessible means (2). FDA staff members also conduct intramural research to inves- tigate the fate and function of transplanted cells and to improve cell product testing strategies
     Url https://www.researchgate.net/profile/Deborah_Hursh/publication/230762200_FDA_Oversight_of_Cell_Therapy_Clinical_Trials/links/0deec52471cbd0fc14000000/FDA-Oversight-of-Cell-Therapy-Clinical-Trials.pdf


     Search term "Cyber-physical+system"+OR+"Industrial+control+system"+OR+"ICS"+OR+"SCADA"+OR+"Distributed+control+system"+OR+"DCS"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"
     Title Implementing the US FDA guidance on pharmacogenomic data submissions
     Author ['F Goodsaid', 'FW Frueh']
     Venue Environmental and molecular …
     Year 2007
     Abstract The FDA Guidance for Industry: Pharmacogenom- ics Data Submissions was issued in 2005  One of the early proofs-of-concept for this process will be the review of the work of the Predictive Safety Testing Con- sortium [US FDA, 2006b] coordinated by the C-Path Institute
     Url https://onlinelibrary.wiley.com/doi/abs/10.1002/em.20294

